NellOne Therapeutics files provisional patent related to COVID-19

NellOne Therapeutics Inc., the early stage biopharmaceutical company headquartered in Oak Ridge, has announced the filing of a provisional patent application around the usage of the NELL1 signaling protein in the treatment of respiratory viral infections including COVID-19.

The patent application, titled “Methods and Compositions for Treating Tissue Damage Resulting from Viral Infections,” is an extension of the company’s pioneering research into the NELL1 protein as a candidate to treat acute major injuries in soft tissues.

It is also the second major announcement in about a month for the company, the earlier one being the appointment of Bill Malkes as Chief Executive Officer (see our recent article here).

The application details the treatment and prevention of tissue damage and inflammation resulting from COVID-19 or other respiratory viral infections, including the regeneration of compromised upper and lower respiratory tissues via the administration of the NELL1 protein.

Click here to read more.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.